[{"id":"9d2b54f0-0907-4b8a-b5db-69cd00d54eb2","acronym":"SWOG S1608","url":"https://clinicaltrials.gov/study/NCT03269669","created_at":"2021-01-29T07:15:29.475Z","updated_at":"2025-02-25T12:26:46.064Z","phase":"Phase 2","brief_title":"Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma","source_id_and_acronym":"NCT03269669 - SWOG S1608","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • doxorubicin hydrochloride • Gazyva (obinutuzumab) • cyclophosphamide • vincristine • bendamustine • Ukoniq (umbralisib) • Belrapzo (bendamustine RTD)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 01/23/2018","start_date":" 01/23/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"},{"id":"68f3baae-dc4f-43a6-80f0-573ab27bebb5","acronym":"ViPOR","url":"https://clinicaltrials.gov/study/NCT03223610","created_at":"2021-01-18T15:54:35.735Z","updated_at":"2025-02-25T13:39:32.188Z","phase":"Phase 1/2","brief_title":"Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma","source_id_and_acronym":"NCT03223610 - ViPOR","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • lenalidomide • Gazyva (obinutuzumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 145","initiation":"Initiation: 02/09/2018","start_date":" 02/09/2018","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-21"},{"id":"88783755-7459-4207-a7a6-0af081a9d60d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01496976","created_at":"2021-01-18T06:16:27.062Z","updated_at":"2025-02-25T13:48:06.671Z","phase":"Phase 2","brief_title":"Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL","source_id_and_acronym":"NCT01496976","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CD20 • CD5","pipe":"","alterations":" ","tags":["CD20 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Arzerra (ofatumumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 03/30/2012","start_date":" 03/30/2012","primary_txt":" Primary completion: 10/06/2021","primary_completion_date":" 10/06/2021","study_txt":" Completion: 03/25/2025","study_completion_date":" 03/25/2025","last_update_posted":"2025-02-21"},{"id":"e2ff7fb5-f1de-4b7f-9fd4-438675875b61","acronym":"","url":"https://clinicaltrials.gov/study/NCT02160015","created_at":"2021-01-18T10:03:19.018Z","updated_at":"2025-02-25T13:52:04.076Z","phase":"Phase 1","brief_title":"Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery","source_id_and_acronym":"NCT02160015","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD4 • CD5 • FCER2","pipe":"","alterations":" ","tags":["CD20 • CD4 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 05/20/2014","start_date":" 05/20/2014","primary_txt":" Primary completion: 03/27/2017","primary_completion_date":" 03/27/2017","study_txt":" Completion: 08/13/2025","study_completion_date":" 08/13/2025","last_update_posted":"2025-02-20"},{"id":"0a2b6dbc-36dd-467c-bb46-4e7fcb611199","acronym":"CO41942","url":"https://clinicaltrials.gov/study/NCT04246086","created_at":"2023-03-27T23:03:02.854Z","updated_at":"2025-02-25T15:34:35.235Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma","source_id_and_acronym":"NCT04246086 - CO41942","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20 • CD4","pipe":" | ","alterations":" CD20 expression","tags":["CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Recruiting","enrollment":" Enrollment 237","initiation":"Initiation: 08/12/2020","start_date":" 08/12/2020","primary_txt":" Primary completion: 10/15/2028","primary_completion_date":" 10/15/2028","study_txt":" Completion: 10/15/2030","study_completion_date":" 10/15/2030","last_update_posted":"2025-02-10"},{"id":"256f83da-7b60-4240-9f0a-ab88796e2617","acronym":"","url":"https://clinicaltrials.gov/study/NCT06649812","created_at":"2025-02-25T15:37:38.396Z","updated_at":"2025-02-25T15:37:38.396Z","phase":"Phase 2","brief_title":"Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma","source_id_and_acronym":"NCT06649812","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • lenalidomide • Gazyva (obinutuzumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 02/28/2025","start_date":" 02/28/2025","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2025-02-10"},{"id":"53b3407a-20b5-4273-98e0-b8684d9dff01","acronym":"","url":"https://clinicaltrials.gov/study/NCT01829568","created_at":"2021-01-18T08:08:01.489Z","updated_at":"2025-02-25T14:34:07.166Z","phase":"Phase 1","brief_title":"Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma","source_id_and_acronym":"NCT01829568","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD4","pipe":"","alterations":" ","tags":["CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 06/26/2013","start_date":" 06/26/2013","primary_txt":" Primary completion: 05/11/2015","primary_completion_date":" 05/11/2015","study_txt":" Completion: 01/24/2026","study_completion_date":" 01/24/2026","last_update_posted":"2025-02-10"},{"id":"33ca6a18-d45b-42c8-9bb0-e546b4b79d4d","acronym":"GLOBRYTE","url":"https://clinicaltrials.gov/study/NCT06084936","created_at":"2023-10-16T15:12:59.101Z","updated_at":"2025-02-25T16:33:44.879Z","phase":"Phase 3","brief_title":"A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma","source_id_and_acronym":"NCT06084936 - GLOBRYTE","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CCND1","pipe":" | ","alterations":" Chr t(11;14)","tags":["CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • Gazyva (obinutuzumab) • bendamustine • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm)"],"overall_status":"Recruiting","enrollment":" Enrollment 182","initiation":"Initiation: 10/22/2023","start_date":" 10/22/2023","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-07"},{"id":"302e12e8-3d06-4205-8871-3fc4c45bd55f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01856192","created_at":"2021-01-18T08:17:29.922Z","updated_at":"2025-02-25T16:43:43.231Z","phase":"Phase 2","brief_title":"Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT01856192","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK • MYC • CD20 • CD4","pipe":" | ","alterations":" CD20 expression • MYC translocation","tags":["ALK • MYC • CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression • MYC translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 349","initiation":"Initiation: 08/27/2013","start_date":" 08/27/2013","primary_txt":" Primary completion: 03/26/2020","primary_completion_date":" 03/26/2020","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"65e8d7c8-cd05-4be4-b31d-3d804c0d4afd","acronym":"NCI-2009-01173","url":"https://clinicaltrials.gov/study/NCT00843882","created_at":"2023-11-21T16:15:34.542Z","updated_at":"2025-02-25T16:43:32.520Z","phase":"Phase 3","brief_title":"Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia","source_id_and_acronym":"NCT00843882 - NCI-2009-01173","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PTPRC • CDC25C • GNRP","pipe":"","alterations":" ","tags":["PTPRC • CDC25C • GNRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Retacrit (epoetin alfa-epbx)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 247","initiation":"Initiation: 01/29/2009","start_date":" 01/29/2009","primary_txt":" Primary completion: 07/08/2019","primary_completion_date":" 07/08/2019","study_txt":" Completion: 10/02/2025","study_completion_date":" 10/02/2025","last_update_posted":"2025-02-06"},{"id":"e7cf2c99-6cfe-4015-9ca9-b9a242d379a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04739813","created_at":"2021-02-05T13:56:26.764Z","updated_at":"2025-02-25T16:38:14.078Z","phase":"Phase 1","brief_title":"Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma","source_id_and_acronym":"NCT04739813","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • BCL6 • UGT1A1","pipe":" | ","alterations":" MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement • UGT1A1*1*1 • UGT1A1 mutation","tags":["BCL2 • BCL6 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement • UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • lenalidomide • Gazyva (obinutuzumab) • Polivy (polatuzumab vedotin-piiq)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 07/09/2021","start_date":" 07/09/2021","primary_txt":" Primary completion: 10/29/2025","primary_completion_date":" 10/29/2025","study_txt":" Completion: 10/29/2030","study_completion_date":" 10/29/2030","last_update_posted":"2025-02-06"},{"id":"37db9b88-cfea-407b-b290-ec67bb7844d2","acronym":"EPCORE NHL-5","url":"https://clinicaltrials.gov/study/NCT05283720","created_at":"2022-03-17T12:53:27.504Z","updated_at":"2025-02-25T16:54:10.677Z","phase":"Phase 2","brief_title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05283720 - EPCORE NHL-5","lead_sponsor":"Genmab","biomarkers":" BCL2 • CD20 • CCND1 • BCL6","pipe":" | ","alterations":" Chr t(11;14)","tags":["BCL2 • CD20 • CCND1 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • Jaypirca (pirtobrutinib) • Epkinly (epcoritamab-bysp) • Polivy (polatuzumab vedotin-piiq) • golcadomide (CC-99282)"],"overall_status":"Recruiting","enrollment":" Enrollment 622","initiation":"Initiation: 06/14/2022","start_date":" 06/14/2022","primary_txt":" Primary completion: 11/01/2032","primary_completion_date":" 11/01/2032","study_txt":" Completion: 11/01/2032","study_completion_date":" 11/01/2032","last_update_posted":"2025-02-04"},{"id":"5d7df1e1-4350-4f4d-84d5-eafdf2cf1c33","acronym":"EPCORE DLBCL-3","url":"https://clinicaltrials.gov/study/NCT05660967","created_at":"2022-12-21T14:58:58.070Z","updated_at":"2025-02-25T16:54:37.811Z","phase":"Phase 2","brief_title":"Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT05660967 - EPCORE DLBCL-3","lead_sponsor":"Genmab","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Epkinly (epcoritamab-bysp)"],"overall_status":"Recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 03/06/2023","start_date":" 03/06/2023","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 07/31/2027","study_completion_date":" 07/31/2027","last_update_posted":"2025-02-04"},{"id":"5fb2a2a3-8028-4771-9421-4a4933245c34","acronym":"FIORELLA","url":"https://clinicaltrials.gov/study/NCT03495960","created_at":"2021-01-18T17:12:50.063Z","updated_at":"2025-02-25T17:29:39.803Z","phase":"Phase 2","brief_title":"Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System","source_id_and_acronym":"NCT03495960 - FIORELLA","lead_sponsor":"International Extranodal Lymphoma Study Group (IELSG)","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • temozolomide • Matulane (procarbazine hydrochloride)"],"overall_status":"Completed","enrollment":" Enrollment 72","initiation":"Initiation: 06/15/2019","start_date":" 06/15/2019","primary_txt":" Primary completion: 12/12/2024","primary_completion_date":" 12/12/2024","study_txt":" Completion: 12/12/2024","study_completion_date":" 12/12/2024","last_update_posted":"2025-01-30"},{"id":"eb87323c-0942-4abb-b43f-af01b1dff7f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT06015880","created_at":"2023-12-26T19:17:43.252Z","updated_at":"2025-02-25T17:32:19.406Z","phase":"Phase 1","brief_title":"Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT06015880","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IFNG • CD79B • CD4","pipe":" | ","alterations":" CD79B expression","tags":["IFNG • CD79B • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD79B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/20/2024","start_date":" 05/20/2024","primary_txt":" Primary completion: 06/29/2026","primary_completion_date":" 06/29/2026","study_txt":" Completion: 06/29/2026","study_completion_date":" 06/29/2026","last_update_posted":"2025-01-30"},{"id":"9eacdbab-1a64-457b-a4b2-200a00018493","acronym":"GPL study","url":"https://clinicaltrials.gov/study/NCT05335018","created_at":"2022-04-19T22:56:54.403Z","updated_at":"2025-02-25T12:38:12.292Z","phase":"Phase 2","brief_title":"GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT05335018 - GPL study","lead_sponsor":"Seoul National University Hospital","biomarkers":" BCL6","pipe":" | ","alterations":" CD20 expression","tags":["BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Columvi (glofitamab-gxbm) • poseltinib (HM71224)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 76","initiation":"Initiation: 05/30/2022","start_date":" 05/30/2022","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2024-12-16"},{"id":"23dbac8b-ecfd-4311-9f6c-4354922bc4b0","acronym":"RELEVANCEt","url":"https://clinicaltrials.gov/study/NCT01650701","created_at":"2021-01-18T07:06:43.879Z","updated_at":"2025-02-25T14:33:35.027Z","phase":"Phase 3","brief_title":"A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma","source_id_and_acronym":"NCT01650701 - RELEVANCEt","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • bendamustine"],"overall_status":"Completed","enrollment":" Enrollment 1030","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 05/31/2017","primary_completion_date":" 05/31/2017","study_txt":" Completion: 04/30/2024","study_completion_date":" 04/30/2024","last_update_posted":"2024-10-09"},{"id":"ade707b7-5e5b-4f00-a824-2c91c94d8afe","acronym":"","url":"https://clinicaltrials.gov/study/NCT04578600","created_at":"2021-01-18T21:51:14.278Z","updated_at":"2025-02-25T14:29:38.782Z","phase":"Phase 1","brief_title":"CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma","source_id_and_acronym":"NCT04578600","lead_sponsor":"Joseph Tuscano","biomarkers":" CD20 • CD4","pipe":"","alterations":" ","tags":["CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Gazyva (obinutuzumab) • Onureg (azacitidine oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 10/23/2020","start_date":" 10/23/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-09-19"},{"id":"cb4474a3-cced-4bbc-87d9-d4328097a450","acronym":"","url":"https://clinicaltrials.gov/study/NCT02529852","created_at":"2021-01-18T12:13:55.908Z","updated_at":"2025-02-25T14:35:48.868Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT02529852","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • doxorubicin hydrochloride • Gazyva (obinutuzumab) • cyclophosphamide • vincristine"],"overall_status":"Completed","enrollment":" Enrollment 59","initiation":"Initiation: 11/04/2015","start_date":" 11/04/2015","primary_txt":" Primary completion: 10/31/2022","primary_completion_date":" 10/31/2022","study_txt":" Completion: 10/31/2022","study_completion_date":" 10/31/2022","last_update_posted":"2024-09-19"},{"id":"259ce71b-5eef-4e8b-8117-2864d12c696a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01472562","created_at":"2021-01-18T06:08:26.175Z","updated_at":"2025-02-25T14:33:09.941Z","phase":"Phase 2","brief_title":"Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma","source_id_and_acronym":"NCT01472562","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" CD20 • CCND1 • CD5 • CCND2 • MME • FCER2","pipe":" | ","alterations":" CCND1 overexpression • CCND2 overexpression","tags":["CD20 • CCND1 • CD5 • CCND2 • MME • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 overexpression • CCND2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 07/29/2011","start_date":" 07/29/2011","primary_txt":" Primary completion: 04/01/2014","primary_completion_date":" 04/01/2014","study_txt":" Completion: 07/30/2023","study_completion_date":" 07/30/2023","last_update_posted":"2024-07-16"},{"id":"2dd784c3-2556-4e8f-858c-e43a2f1be9da","acronym":"realMIND","url":"https://clinicaltrials.gov/study/NCT04981795","created_at":"2021-07-29T14:53:08.563Z","updated_at":"2024-07-02T16:34:26.241Z","phase":"","brief_title":"realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL","source_id_and_acronym":"NCT04981795 - realMIND","lead_sponsor":"Incyte Corporation","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 translocation • BCL2 translocation","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 translocation • BCL2 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Monjuvi (tafasitamab-cxix)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/20/2021","start_date":" 09/20/2021","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2024-06-13"},{"id":"ad50b74e-df77-4142-938b-467110fb4a75","acronym":"SYMPHONY-1","url":"https://clinicaltrials.gov/study/NCT04224493","created_at":"2023-06-02T17:05:31.313Z","updated_at":"2024-07-02T16:34:26.311Z","phase":"Phase 3","brief_title":"Study of Tazemetostat Versus Placebo When Given in Combination With Lenalidomide and Rituximab in Participants With Relapsed/Refractory Follicular Lymphoma","source_id_and_acronym":"NCT04224493 - SYMPHONY-1","lead_sponsor":"Epizyme, Inc.","biomarkers":" EZH2","pipe":" | ","alterations":" EZH2 mutation","tags":["EZH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EZH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • Tazverik (tazemetostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 612","initiation":"Initiation: 06/11/2020","start_date":" 06/11/2020","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2024-06-13"},{"id":"82776520-b06e-46e0-b799-6acc9cecb384","acronym":"","url":"https://clinicaltrials.gov/study/NCT05615636","created_at":"2022-11-14T14:58:16.761Z","updated_at":"2024-07-02T16:34:36.912Z","phase":"Phase 2","brief_title":"A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL","source_id_and_acronym":"NCT05615636","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Monjuvi (tafasitamab-cxix) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 04/28/2023","start_date":" 04/28/2023","primary_txt":" Primary completion: 08/19/2025","primary_completion_date":" 08/19/2025","study_txt":" Completion: 08/19/2027","study_completion_date":" 08/19/2027","last_update_posted":"2024-06-10"},{"id":"b58e8f18-6ad1-49e6-929a-a6948bafdb8f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04447716","created_at":"2021-01-18T21:24:06.674Z","updated_at":"2024-07-02T16:34:27.618Z","phase":"Phase 1","brief_title":"An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment","source_id_and_acronym":"NCT04447716","lead_sponsor":"Thomas Jefferson University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • lenalidomide • Truxima (rituximab-abbs) • Rituxan Hycela (rituximab/hyaluronidase) • Riabni (rituximab-arrx)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/16/2020","start_date":" 10/16/2020","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-06-10"}]